Abstract
Objective: Liraglutide 3.0 mg daily dose is marketed under the brand name Saxenda and was recently approved by both the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) as adjunct to a comprehensive lifestyle intervention to achieve weight loss.
Design: Human studies using liraglutide 3.0 mg daily dose were selected through search based on PubMed listings and the Clinical trials.gov database using the term “liraglutide”.
Results: During 56 weeks of treatment, liraglutide 3.0 mg treatment resulted in 5.9-8.0% weight reduction, while the placebo-subtracted weight loss was 3.9-6.0%. The proportion of treated patients with ≥ 5% weight loss was 50-76%, while the placebo-subtracted proportion was 29-46%. Liraglutide 3.0 mg treatment also induced a decrease in waist circumference, serum triglycerides, insulin resistance, blood pressure and an increase in high density lipoprotein-cholesterol (HDL-C). The most common side effects were nausea, hypoglycemia, diarrhea, constipation, vomiting and headache. In the majority of patients liraglutide 3.0 mg was well tolerated.
Conclusion: Liraglutide 3.0 mg appears to be an effective adjunct to a comprehensive lifestyle intervention to achieve weight reduction and treat obesity-related comorbidities.
Keywords: Liraglutide, glucagon-like peptide-1 agonist, weight loss, lipids, blood pressure, side effects.
Current Vascular Pharmacology
Title:The Current Role of Liraglutide in the Pharmacotherapy of Obesity
Volume: 14 Issue: 2
Author(s): Georgios A. Christou, Niki Katsiki and Dimitrios N. Kiortsis
Affiliation:
Keywords: Liraglutide, glucagon-like peptide-1 agonist, weight loss, lipids, blood pressure, side effects.
Abstract: Objective: Liraglutide 3.0 mg daily dose is marketed under the brand name Saxenda and was recently approved by both the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) as adjunct to a comprehensive lifestyle intervention to achieve weight loss.
Design: Human studies using liraglutide 3.0 mg daily dose were selected through search based on PubMed listings and the Clinical trials.gov database using the term “liraglutide”.
Results: During 56 weeks of treatment, liraglutide 3.0 mg treatment resulted in 5.9-8.0% weight reduction, while the placebo-subtracted weight loss was 3.9-6.0%. The proportion of treated patients with ≥ 5% weight loss was 50-76%, while the placebo-subtracted proportion was 29-46%. Liraglutide 3.0 mg treatment also induced a decrease in waist circumference, serum triglycerides, insulin resistance, blood pressure and an increase in high density lipoprotein-cholesterol (HDL-C). The most common side effects were nausea, hypoglycemia, diarrhea, constipation, vomiting and headache. In the majority of patients liraglutide 3.0 mg was well tolerated.
Conclusion: Liraglutide 3.0 mg appears to be an effective adjunct to a comprehensive lifestyle intervention to achieve weight reduction and treat obesity-related comorbidities.
Export Options
About this article
Cite this article as:
Christou A. Georgios, Katsiki Niki and Kiortsis N. Dimitrios, The Current Role of Liraglutide in the Pharmacotherapy of Obesity, Current Vascular Pharmacology 2016; 14 (2) . https://dx.doi.org/10.2174/1570161113666150615111951
DOI https://dx.doi.org/10.2174/1570161113666150615111951 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Risk Factors, Metabolic Complications, & the Natural Course of CKD in Children
Current Hypertension Reviews Assessment and Imaging of the Cerebrovascular Glycocalyx
Current Neurovascular Research Microbiome Medicine: Microbiota in Development and Management of Cardiovascular Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacological Modulation of Microparticle Release: New Strategies for the Management of Atherothrombotic Vascular Disorders
Current Pharmaceutical Design On Electromagnetic Ablation of Biological Tissues: A Review
Recent Patents on Electrical Engineering Hypertensive Versus HIV-infected Patients: Who Has the Greatest Target Organ Damage? Comparison of Carotid Plaque Prevalence, Intima Media Thickness and Renal Resistive Index in the Two Groups of Patients
Current Hypertension Reviews UPLC-MS for Identification of Quercetin Derivatives in Cuphea glutinosa Cham. & Schltdl (Lythraceae) and Evaluation of Antifungal Potential
Current Pharmaceutical Analysis Design, Synthesis, and Biological Evaluation of Novel Tetramethylpyrazine- nitrone Derivatives as Antioxidants
Letters in Drug Design & Discovery Effects of Metformin-Single Therapy on the Level of Inflammatory Markers in Serum of Non-Obese T2DM Patients with NAFLD
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Nitric Oxide Synthase Inhibitors in Schizophrenia
Current Medicinal Chemistry Takotsubo Cardiomyopathy and COVID-19: A Case Report and Literature Review
Current Cardiology Reviews The Pathophysiology of Heme in the Brain
Current Alzheimer Research Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease
Current Vascular Pharmacology Insights into the Pathogenesis and Intervention of Atherosclerosis
Vascular Disease Prevention (Discontinued) Multiplicity of Ca2+ Messengers and Ca2+ Stores: A Perspective from Cyclic ADP-Ribose and NAADP
Current Molecular Medicine Traditional Chinese Medicine Network Pharmacology in Cardiovascular Precision Medicine
Current Pharmaceutical Design Oxidative Stress, Endothelial Function and Angiogenesis Induced by Cell Therapy and Gene Therapy
Current Pharmaceutical Biotechnology HIF Prolyl 4-Hydroxylases and their Potential as Drug Targets
Current Pharmaceutical Design Older Adults with Amnestic Mild Cognitive Impairment Exhibit Exacerbated Gait Slowing under Dual-Task Challenges
Current Alzheimer Research An Overview on Cardiovascular Protective Effects of Catechins
Cardiovascular & Hematological Disorders-Drug Targets